To find a novel acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor with anti-lipid peroxidative activity, a series of tetrahydroisoquinoline derivatives were synthesized and evaluated. A compound with a N-(4-hydroxy-2,3,5-trimethylphenyl)carbamoyl moiety at the 3-position and an octanoyl moiety at the 2-position (7) was demonstrated to show anti-foam cell formation activity stronger than and anti-lipid peroxidative activity comparable to those of Pactimibe, while it was hardly absorbed orally. To increase its bioavailability, the acyl chain at the 2-position was shortened and various polar or basic moieties were introduced at the 7-position of 7. Among the synthesized derivatives, (S)-7-dimethylamino-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-isobutyryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride (21) showed about 16-fold stronger anti-foam cell formation activity, 3-fold stronger hepatic ACAT inhibitory activity, similar anti-low density lipoprotein (LDL) oxidative activity and 2-fold more potent protective activity against macrophage cell death by oxidative stress in comparison with Pactimibe. Compound 21 was efficiently absorbed after oral administration at 10 mg/kg in rats and dogs and its C max values were higher than its IC 50 values for in vitro activities. In conclusion, a tetrahydroisoquinoline structure is a useful scaffold for designing a phenolic anti-oxidative ACAT inhibitor, and compound 21 is expected to effectively prevent atherosclerosis.
A great number of acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors have been reported as potential hypolipidemic drugs and anti-atherosclerotic drugs, since ACAT plays an important role in intestinal absorption and hepatic secretion of cholesterol and accumulation of cholesterol in macrophages in atherosclerotic plaque [1] [2] [3] [4] ; however, none of the reported inhibitors have been successfully developed. Most of them were highly lipophilic, since ACAT inhibitory activity is dependent on the inhibitor's lipophilicity, 5, 6) and were thus demonstrated to have low bioavailability. We previously synthesized a new indoline-based ACAT inhibitor, Pactimibe, with a carboxymethyl group at the 5-position, which showed moderate ACAT inhibitory activities; however, it was highly water soluble, and showed good oral absorption. 7) Pactimibe also has potent anti-oxidative activities, which were expected to exert synergetic anti-atherosclerotic effects with ACAT inhibitory activities, since oxidized low density lipoprotein (LDL) is taken up by macrophages and then cholesterol is esterified by ACAT to be accumulated in foam cells in atherosclerosis. Pactimibe decreased atherosclerotic areas in apo-E knockout mice and stabilized aortic plaques in Watanabe heritable hyperlipidemic rabbits (WHHL rabbits) 8, 9) ; however, a clinical study using an intravascular-ultrasonography catheter did not show the retardation of plaques at a dose of 100 mg in patients with coronary artery disease (CAD). 10) Pactimibe may have not fully inhibited plaque ACAT activity, and/or its ACAT-inhibitory and anti-oxidative activities may have not exerted synergetic anti-atherosclerotic effects in humans. The anti-oxidative activity of Pactimibe is due to its indoline structure, of which the tertiary amine at the 1-position chemically resembles that of aromatic dialkylamine. Indeed, ACAT inhibitors containing dimethylamino moiety, such as NTE-122, also show potent anti-oxidative activities 11) ; however, the pharmacological effects of the aromatic amine-derived anti-oxidative activities have not been elucidated in atherosclerosis. On the other hand, a number of phenolic compounds have been reported to have anti-oxidative activities. a-Tocopherol and Probucol have been reported to show anti-atherosclerotic effects, probably due to their preventive activities against LDL oxidation. 12, 13) During the course of studies to find a new ACAT inhibitor with structural and biological properties different from Pactimibe, a tetrahydroisoquinoline derivative with a N-(4-hydroxy-2,3,5-trimethylphenyl)carbamoyl moiety at the 3-position and an octanoyl moiety at the 2-position (7) was found to have ACAT inhibitory and anti-oxidative activities comparable to those of Pactimibe, but to show poor bioavailability. To increase the bioavailability of 7, a series of tetrahydroisoquinoline derivatives with polar or basic moieties at the 7-position were synthesized and evaluated.
Chemistry The synthetic routes of various 2-acyl-Naryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamides are shown in Chart 1-3. In Chart 1, the synthetic routes of Naryl-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamides with no substitution at the 7-position (7, 8, 10 ) are outlined. The starting material 1, which was easily prepared from L-phenylalanine, 14) was acylated with octanoyl chloride to give 2. The methyl ester of 2 was hydrolyzed with NaOH to provide carboxylic acid (3) , which was condensed with three anilines, 4-amino-2,3,6-trimethylphenyl acetate (4), 15) 2,6-diisopropylaniline, and 2,6-diisopropyl-4-nitroaniline (5) reduced by hydrogenation, and the product was converted to a HCl salt (10) . In Chart 2, the synthetic routes of 2-acyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide derivatives with an amino, dimethylamino, acetylamino, methanesulfonylamino, pyrrolidinyl, and morpholinyl moiety at the 7-position (11-28) are outlined.
Starting material 29, which was obtained from nitration of 1, 16) was protected with Cbz group, and the nitro moiety was reduced selectively with iron, protected with Boc 2 O, and then hydrolyzed to give 30. After condensation with the aniline 4, the Cbz group was removed to give 31. Compound 31 was acylated with eight acyl chlorides, and deprotected of the acetyl moiety and the Boc group to afford 11-18. Sepa-rately, compound 29 was protected with Boc 2 O to give 32, and the nitro moiety of 32 was converted to dimethylamino moiety by reductive alkylation to afford compound 33, which was converted to 34 by hydrolyzation, condensation with the aniline 4 using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) · HCl, and removal of the Boc group. Compound 34 was acylated with five acyl chlorides, and the products were hydrolyzed and treated with hydrochloride to give 19-23. Likewise, the nitro moiety of 32 was reduced, and the generated amino moiety was cyclized to 1-pyrrolidinyl moiety to give 35, and then compound 35 was converted to 24 and 25 via 36 as described in the synthesis of 19-23. To synthesize of 26, the Boc group of 32 was changed to hexanoyl moiety, and the nitro moiety was reduced to give 37, and then the amino moiety of 37 was cyclized with bis(2-chloroethyl) ether to give 38 having a morpholinyl moiety. Compound 38 was converted to 26 in a similar manner to the synthesis of 19-23. Separately, compound 32 was reduced, and acetylated to give 39. Compound 39 was treated with hydrochloride, and then acylated with hexanoyl chloride to afford 40. Compound 40 was converted to 27 as described in the synthesis of 19-23. Compound 28 was obtained directly from 13 by mesylation with pyridine as a base.
In Chart 3, the synthetic routes of 2-acyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide derivatives with a hydroxyl, piperazinyl, and dialkylaminomethyl moiety at the 7-position (41-46) are outlined. To synthesize 41, starting compound 47, which was prepared from L-tyrosine in accordance with a reported method, 17) was converted to 48 with the triflate moiety at the 7-position by the usual methods. Compound 48 was reacted with 1-benzylpiperazine by palladium-catalyzed amination to give 49, 18) and the Boc group at the 2-position was changed to the hexanoyl moiety to afford 50. Compound 50 was hydrolyzed, and condensed with the aniline 4 to give 51. The acetyl moiety of 51 was removed, and then the benzyl protection group of piperazinyl moiety was removed by hydrogenolyzation with Pd(OH) 2 -C to afford 41. To synthesize 42, compound 47 was protected with benzyl bromide at the 7-position by temporary protection with Boc group at the 2-position, to give 52. Compound 52 was acylated with hexanoyl chloride, and deiodination was achieved by hydrogenolyzation with Pd-C to give 53 without debenzylation. Compound 53 was converted to 42 via 54 in a similar way to the conversion of 50 to 41. Separately, to synthesize 57-59, the triflate moiety of 48 was replaced with a nitrile moiety by application of the palladium-catalyzed coupling reaction, 19) and the nitrile was hydrogenated in the presence of ammonia and Pd-C, and then the generated aminomethyl moiety was protected with CbzCl to give 55. Conversion of 55 to 56 was accomplished as mentioned in the synthesis of 19-23. The Cbz group of 56 was removed by hydrogenolyzation, and the aminomethyl moiety of the product was alkylated by reductive alkylation to give 57 and 58, and cyclized with 1,4-dibromobutane to give 59. The synthesis of 62 with an asymmetric tertiary amino moiety was difficult by this method; therefore, an alternative route was utilized. Compound 47 was converted to 60, and the triflate moiety of 60 was replaced with a nitrile moiety, and the nitrile was reduced to aldehyde by Raney nickel. 20) Selective reduction of the aldehyde was accomplished with tert-butylamine borane complex, 21) and the product was hydrolyzed to give 61. After condensation of 61 with the aniline 4, the hydroxyl moiety was mesylated, and to the mesylate was attached N-methylpropylamine to give 62. Compounds 57-59, 62 were hydrolyzed, and the products were converted to HCl salts (43, 44, 46) or obtained as a free form (45), respectively.
Results and Discussion
Pactimibe exerted inhibitory effects on macrophage ACAT activities and LDL oxidation, and was efficiently absorbed orally, being expected to show potent anti-atherosclerotic effects by the synergism of both activities; however, Pactimibe failed to show a plaque-reducing effect in CAD patients. 10) Pactimibe may have not fully inhibited plaque ACAT activity and LDL oxidation, or both activities may not be effective in human atherosclerotic plaque. To clarify these possibilities, it is important to find new bioavailable ACAT inhibitors with structural and biological properties different from Pactimibe and to experimentally and clinically investigate its effects on atherosclerosis.
In the present study, a tetrahydroisoquinoline structure instead of indoline structure was employed to design new ACAT inhibitors. To find the lead compound, 3 derivatives (7, 8, 10) were synthesized and their log D 7.0 , inhibitory activities against rabbit hepatic ACAT, foam cell formation induced by acetyl LDL, and LDL peroxidation were determined (Table 1) . Among them, compound 7 showed the most potent inhibitory activities against ACAT, foam cell formation, and LDL peroxidation; however, all these compounds were highly lipophilic and were not detected in plasma after oral administration at 10 mg/kg in rats. Therefore, to decrease lipophilicity and increase bioavailability, the acyl chain at the 2-position was shortened and a polar or basic moiety was introduced at the 7-position in compound 7.
In Table 2 , compounds with a primary amino group at the 7-position and various acyl groups (11) (12) (13) (14) (15) (16) (17) (18) had lower log D 7.0 than 1.6, and still had 1.3 to 7.0-fold more potent anti-foam cell formation activities than Pactimibe. The activities increased in a log D 7.0 -dependent manner, and tended to be higher with straight alkyl chains than branched alkyl and straight alkenyl chains. They showed poor oral absorption; a primary amino moiety may have been easily metabolized. The most potent compound 13 with activity 7-fold higher than Pactimibe and comparable to 7 showed low plasma concentration after oral administration at 10 mg/kg in rats (C max : 0.33 mg/ml). Compounds with a dimethylamino group at the 7-position (19) (20) (21) (22) (23) by macrophages and foam cell formation, and preventing oxidative stress-induced foam cell death, resulting in the reduction of cell debris, extracellular cholesterol deposition and inflammatory response. Probucol and KY-455, an indolinebased ACAT inhibitor, have been reported to attenuate the oxidative stress-induced apoptosis of THP-1 derived macrophages. 22, 23) Compound 21 and Pactimibe concentrationdependently decreased macrophage cell death induced by co-incubation with LDL and Cu 2ϩ ( Table 4 ). The effect of compound 21 was 2-fold stronger than Pactimibe, whereas both compounds showed similar anti-LDL oxidative activities. The C max of compound 21 was higher in rats and lower in dogs than Pactimibe, and exceeded the IC 50 values for foam cell formation, LDL oxidation and cell death, anticipating that 21 would exert these effects in vivo. Phenolic antioxidants such as Probucol are also known to have anti-inflammatory effects via inhibition of adhesion molecule expression. 24 ) Future studies will reveal whether phenolic ACAT inhibitors have such anti-inflammatory effects beneficial for atherosclerosis therapy.
In conclusion, the present study demonstrated that a tetrahydroisoquinoline structure with a phenol moiety is useful for the design of bioavailable anti-oxidative ACAT inhibitors, and that 21 is expected to show anti-atherosclerotic effects by ACAT inhibitory and phenolic anti-oxidative activities.
Experimental
General Procedures Chemicals were obtained from commercial sources and used without purification. Reactions were monitored by TLC on Merck precoated silica gel 60 F 254 (0.25 mm) plates. Column chromatography was performed on silica gel (Daisogel No. 1001W; Daiso, Osaka, Japan). Melting points were measured on melting point apparatus (MP-500P; Yanaco, Kyoto, Japan) and are uncorrected. IR spectra were obtained with an infrared spectrometer (FT-IR 8200PC; Shimadzu, Kyoto, Japan).
1 H-NMR spectra were recorded on a nuclear magnetic resonance spectrometer at 90 MHz (R-1900; Hitachi, Tokyo, Japan) or 400 MHz (JNM-AL400; JEOL, Tokyo, Japan) using tetramethylsilane as an internal standard. MS spectra were obtained on a QTRAP LC/MS/MS system (API2000; Applied Biosystems, Foster, CA, U.S.A.).
Procedure for the Synthesis of 7 4-Amino-2,3,6-trimethylphenyl Acetate (4): 2,3,6-Trimethylphenol was nitrated as described in a previous article.
15) The nitrated product was acetylated with AcCl and Et 3 N, and hydrogenated in the presence of Pd-C in a standard manner to give 4 as a crystalline solid (78% yield). Methyl (S)-2-Octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (2): To a solution of 1 (1.00 g, 5.23 mmol) in CH 2 Cl 2 (10 ml) were added Et 3 N (1.09 ml, 7.82 mmol) and n-octanoyl chloride (0.98 ml, 5.7 mmol), and the mixture was stirred at room temperature for 3 h. The mixture was washed with 10% citric acid solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give 2 as an oil (1.32 g, 80% yield). (S)-2-Octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid (3): To a solution of 2 (1.00 g, 3.15 mmol) in MeOH (10 ml) was added 5.0 M NaOH aqueous solution (1.26 ml, 6.3 mmol) at room temperature, and the mixture was stirred at 50°C for 1 h. After evaporation under reduced pressure, water and 6 M hydrochloric acid (1.1 ml) were added, and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure to give 3 as an oil (947 mg, 99% yield). (S)-N-(4-Hydroxy-2,3,5-trimethylphenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (7): To a solution of 4-amino-2,3,6-trimethylphenyl acetate (4) (665 mg, 2.19 mmol) and compound 3 (364 mg, 1.88 mmol) in CH 2 Cl 2 (7 ml) in an ice bath were added pyridine (0.46 ml, 5.7 mmol) and POCl 3 (0.28 ml, 3.0 mmol), and the mixture was stirred for 15 min. AcOEt was added, and the mixture was washed with 10% citric acid solution, saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give 2,3,6-trimethyl-4-{[(S)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino}phenyl acetate (6) as a powder (580 mg). To a solution of 6 (550 mg, 1.15 mmol) in MeOH (11 ml) was added 1.0 M LiOH aqueous solution (3.5 ml, 3.5 mmol), and the mixture was stirred at room temperature for 1 h. After addition of 6 M hydrochloric acid (0.6 ml), the mixture was concentrated under reduced pressure. The residue was extracted with CH 2 Cl 2 , and the organic layer was washed with brine, dried over Na 2 SO 4 (S)-N-(4-Amino-2,6-diisopropylphenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Hydrochloride (10): To a solution of 3 (600 mg, 1.98 mmol) and compound 5 (396 mg, 1.80 mmol) in CH 2 Cl 2 (6 ml) were added pyridine (0.48 ml, 5.9 mmol) and POCl 3 (0.24 ml, 2.6 mmol) in an ice bath, and the mixture was stirred for 3 h. The mixture was washed with 10% citric acid solution, saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give (S)-N-(2,6-diisopropyl-4-nitrophenyl)-2-octanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (9) (812 mg). A solution of 9 (795 mg, 1.57 mmol) in MeOH (10 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (160 mg) at 40°C for 2.5 h. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography. To a solution of the residue in MeOH (2.6 ml) was added 10 M HCl in i-PrOH (0.13 ml, 1.3 mmol) in an ice bath. After evaporation under reduced pressure, Et 2 O was added, and the precipitate formed was collected by filtration to give 10 as a solid (453 Methyl (S)-2-tert-Butoxycarbonyl-7-dimethylamino-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (33): A solution of 32 (3.57 g, 10.6 mmol) in MeOH (50 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (0.25 g) at room temperature for 1.5 h. To the mixture were added formalin 2.4 ml (32 mmol) and 2.0 M hydrochloric acid (1.05 ml, 2.1 mmol), and the mixture was hydrogenated at 0.3 MPa for 3 h. After filtration, the filtrate was evaporated under reduced pressure. A solution of the residue in AcOEt was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was recrystallized from (11 ml, 11 mmol) , and the mixture was stirred at room temperature for 2 h. After neutralization with 5% citric acid solution, the mixture was concentrated under reduced pressure, and the residue was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in CH 2 Cl 2 (50 ml) in an ice bath were added 4 (1.03 g, 5.33 mmol) and EDC · HCl (1.23 g, 6 .42 mmol), and the mixture was stirred for 30 min. After evaporation under reduced pressure, 5% citric acid solution was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give 4-{[(S)-2-tert-butoxycarbonyl-7-dimethylamino-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino}-2,3,6-trimethylphenyl acetate as a crystalline solid (2.42 g, 91% yield). To a solution of the product (2.38 g, 4.80 mmol) in HCO 2 H (7 ml) in an ice bath was added 10 M HCl in i-PrOH (1.5 ml, 15 mmol), and the mixture was stirred for 30 min. After neutralization with NaHCO 3 , the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. Et 2 O (50 ml) was added, and the precipitate formed was collected by filtration to give 34 as a crystalline solid (1.66 g, 87% yield). 3 (3H, m), 6.60 (1H, s), 7.2-7.7 (3H, m), 9.18 (1H, br-s Methyl (S)-2-Benzyloxycarbonyl-7-nitro-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (65): To a suspension of 29 (8.00 g, 33.9 mmol) in acetone (80 ml) in an ice bath were added MgO (2.05 g, 50.9 mmol) and CbzCl (5.3 ml, 37 mmol), and the mixture was stirred at room temperature for 16 h. After filtration, the filtrate was evaporated under reduced pressure. Hexane (20 ml) was added to the oily residue, and the mixture was stirred for 30 min. The supernatant was removed by decantation, and the residue was dried under reduced pressure to give 65 as an oil (9.30 g, 74% yield). (S)-2-Benzyloxycarbonyl-7-tert-butoxycarbonylamino-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid (30): To a suspension of 65 (9.30 g, 25.1 mmol) in 65% MeOH (260 ml) was added concentrated hydrochloric acid (2.6 ml), and the mixture was heated to be refluxed. Under refluxing, iron powder (5.61 g, 100 mmol) was added in portions over 10 min, and then the mixture was stirred for 1.5 h. Concentrated hydrochloric acid (2.6 ml) and iron powder (2.80 g, 50 mmol) were added, and the mixture was stirred for 1 h. After allowing to cool, the mixture was neutralized with NaHCO 3 . The mixture was filtrated, and the filtrate was concentrated under reduced pressure. The residue was extracted with AcOEt, and the organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in THF (40 ml) was added Boc 2 O (5.48 g, 25.1 mmol), and the mixture was stirred at 45°C for 16 h. After evaporation under reduced pressure, the residue was purified by column chromatography to give a Boc protected derivative. The product was hydrolyzed as described in the preparation of 3 to give 30 as a crystalline solid (6.91 g, 65% yield). 2 ml, 10 mmol) in N,N-dimethylformamide (DMF) (26 ml) was stirred at 60°C for 18 h. After addition of water, the mixture was extracted with AcOEt, and the organic layer was washed with water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give 35 as a crystalline solid (2.25 g, 74% yield). 04 (9H, s), 1.60-1.9.0 (4H, m) 4 (6H, m), 1.71 (3H, s), 2.04 (6H, s), 2.65 (2H, br-t), 2.8-3.5  (3H, m), 3.05 (6H, s), 4.0-6.0 (2H, br), 4.6-5.3 (3H, m), 6.53 (1H, s),  7.2-7.7 (3H, m), 9.01, 9.32 (total 1H, br-s, br-s Procedure for the Synthesis of 26 Methyl (S)-7-Amino-2-hexanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (37): Compound 29 (2.00 g, 8.47 mmol) was acylated with hexanoyl chloride as described in the preparation of 2. A solution of the obtained residue in MeOH (30 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (290 mg) at room temperature for 3.5 h. After filtration, the filtrate was evaporated under reduced pressure, and the residue was purified by column chromatography to give 37 as an oil (2.29 g, 89% yield). , and N-methyl-2-pyrrolidinone (3.5 ml) was heated at 100°C for 5 h. After addition of water, the mixture was extracted with AcOEt, and the organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give 38 as a viscous oil (626 mg, 73% yield). Procedure for the Synthesis of 27 Methyl (S)-7-Acetylamino-2-tertbutoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (39): A solution of 32 (1.00 g, 2.97 mmol) in MeOH (10 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (100 mg) at room temperature for 2 h. After filtration, the filtrate was evaporated under reduced pressure. To a solution of the residue in CH 2 Cl 2 (10 ml) in an ice bath were added Et 3 N (0.62 ml, 4.5 mmol) and Ac 2 O (0.25 ml, 3.5 mmol), and the mixture was stirred for 15 min. The mixture was washed with 5% citric acid solution and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The solid residue was washed with Et 2 O to give 39 as a crystalline solid (740 mg, 71% yield). 6 mmol) slowly, and then the mixture was stirred for 30 min. After evaporation under reduced pressure, 1.0 M hydrochloride acid (25 ml) was added, and the mixture was extracted with Et 2 O. The organic layer was washed with saturated NaHCO 3 solution and brine, dried over Na 2 SO 4 , and then evaporated under reduced pressure. The residue was purified by column chromatography to give 48 as an oil (6.92 g, 97% yield). 51 mmol) were added. The mixture was aerated with nitrogen for 10 min, and stirred at 80°C for 5 h. After allowing to cool, AcOEt was added to the mixture. After filtration, the filtrate was evaporated under reduced pressure, and the residue was purified by column chromatography to give 49 as a viscous oil (745 mg, 50% yield). The Boc group of 49 was changed to hexanoyl moiety, as described in the synthesis of 38 to give 50. An oil. Yield 83%. (50 ml) , and the mixture was stirred at room temperature for 16 h. The mixture was washed with 1.0 M hydrochloric acid and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography. To a solution of the obtained residue in acetone (200 ml) were added benzyl bromide (5.4 ml, 45 mmol) and K 2 CO 3 (7.90 g, 57.2 mmol), and the mixture was stirred at 60°C for 2.5 h. After addition of AcOEt (100 ml), the mixture was filtered, and the filtrate was evaporated under reduced pressure. Methyl (S)-7-Benzyloxy-2-hexanoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (53): Compound 52 (4.00 g, 6.83 mmol) was acylated with hexanoyl chloride, as described in the preparation of 2. A solution of the residue in MeOH (40 ml) was hydrogenated at 0.3 MPa in the presence of 10% Pd-C (200 mg) at 25°C for 2 h. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography to give 53 as an oil (1.93 g, 71% yield). Methyl (S)-2-tert-Butoxycarbonyl-7-cyano-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (64): After a suspension of Pd(OAc) 2 (153 mg, 0.579 mmol) and rac-BINAP (467 mg, 0.750 mmol) in dehydrated N-methyl-2-pyrrolidinone (NMP) (3 ml) was stirred at room temperature for 1 h under a nitrogen atmosphere, KCN (892 mg, 13.7 mmol) and a solution of 48 (3.00 g, 6.83 mmol) in NMP (6 ml) were added, and the mixture was stirred at 80°C for 10 h. After allowing to cool, water (60 ml) and Et 2 O (20 ml) were added, and the mixture was stirred for 10 min. After filtration, the filtrate was extracted with Et 2 O. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. After the residue had been purified by column chromatography, the residue was washed with hexane, and the precipitate was collected by filtration to give 64 as a crystalline solid (1.65 g, 76% yield). IR (neat) cm 7-Benzyloxycarbonylaminomethyl-2-tert-butoxycarbnoyl-2-(2,2-dimethylpropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (55): A mixture of 64 (2.19 g, 6.92 mmol), 28% aqueous ammonia (8.4 g, 0.14 mol), and MeOH (22 ml) was hydrogenated at 0.4 MPa in the presence of 20% Pd(OH) 2 -C (0.22 g) at 35°C for 15 h. After filtration, the filtrate was evaporated under reduced pressure. A solution of the residue in CHCl 3 was dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography to give an aminomethyl derivative as an oil (712 mg, 32% yield). To a solution of the product (900 mg, 2.81 mmol) in AcOEt (9 ml) were added MgO (340 mg, 8.43 mmol) and CbzCl (0.60 ml, 4.2 mmol), and the mixture was stirred at room temperature for 24 h. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography to give 55 as an oil (882 mg, 69% yield). 
(MϩH ϩ
). 1 H-NMR (DMSO-d 6 ) d: 1.
